Achievements and Results

-   Abnormal spliceoform of secretin receptor involved in pancreatic carcinoma identified

-   Dual antibody sandwitch enzyme-linked immunosorbent assay developed, with promising results, which could possibly lead to a serum


The Problem

Pancreatic and bile duct carcinomas represent highly aggressive malignancies that evolve from secretin receptor-rich ductular cells. With premessenger RNA splicing abnormalities common in cancer, the expert was tasked with evaluating whether an abnormal secretin receptor spliceoform was present, characterizing it, and developing a serum assay for it.


The Solution

Cancer cell lines and healthy and neoplastic tissue were studied by nested reverse transcription polymerase chain reaction and sequencing. A promising spliceoform was isolated and characterized, and monoclonal antibodies were raised to 2 distinct regions. A dual antibody enzyme-linked immunosorbent assay was developed and applied to blinded serum samples from 26 patients with pancreatic carcinoma, 10 patients with chronic pancreatitis, and 14 controls.

Each of 9 pancreatic cancer specimens and no normal tissue expressed a secretin receptor variant with exons 3 and 4 deleted. This encoded a 111- residue peptide with its first 43 residues identical to wild-type receptor, but, subsequent to a shift in coding frame and early truncation, the next 68 residues were unique in the transcriptome/proteome. This nonfunctional soluble protein did not bind or signal in response to secretin and was secreted from transfected MiaPaCa-2 cells. Elevated serum levels of this variant were present in 69% of pancreatic cancer patients, 60% of chronic pancreatitis patients, and 1 of 14 controls.


Conclusion and Benefits

We identified a novel abnormal spliceoform of the secretin receptor in pancreatic and bile duct cancers and developed a dual antibody sandwich enzyme-linked immunosorbent assay to measure it in the circulation. Initial application of this assay in patients with pancreatic cancer and chronic pancreatitis was promising, but additional  validation will be required to evaluate its clinical utility.


To see the resume of the expert associated with this case study, see the link below.

Resume of EIG Biotechnology, Assay Validation Expert Consultant Resume


Let us quickly locate the best and most qualified expert or expertise you need.


Full Name*
Please fill in the required field.

Please fill in the required field.

Please fill in the required field.

Please fill in the required field.

Client Need
Please fill in the required field.

Invalid Input


Peter Habicht, Lead Consultant
Peter specializes in welding and metallurgical engineer with 40 years industry experience in commercial nuclear power plant construction.


  • Poly(methylmethacrylate) Manufacturing Operations / Processes Consultants
  • Cell Phone Technologies Expert


Our Business Model
At Kevin Kennedy Associates, we’ve revolutionized the consulting business by streamlining the way our clients interact with experts.